Ginkgo Bioworks (NYSE:DNA) versus Bio-Rad Laboratories (NYSE:BIO) Head-To-Head Analysis

Ginkgo Bioworks (NYSE:DNA) and Bio-Rad Laboratories (NYSE:BIO) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Ginkgo Bioworks and Bio-Rad Laboratories”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$132.42 million	3.59	-$312.76 million	($5.01)	-1.41
Bio-Rad Laboratories	$2.59 billion	3.91	$759.90 million	$8.25	45.90

Bio-Rad Laboratories has higher revenue and earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ginkgo Bioworks and Bio-Rad Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
Bio-Rad Laboratories	8.59%	3.54%	2.48%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Ginkgo Bioworks and Bio-Rad Laboratories, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2	2	0	0	1.50
Bio-Rad Laboratories	0	4	1	0	2.20

Ginkgo Bioworks presently has a consensus target price of $6.33, suggesting a potential downside of 10.38%. Bio-Rad Laboratories has a consensus target price of $343.33, suggesting a potential downside of 9.32%. Given Bio-Rad Laboratories’ stronger consensus rating and higher probable upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Ginkgo Bioworks.

Risk and Volatility

Ginkgo Bioworks has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.

Summary

Bio-Rad Laboratories beats Ginkgo Bioworks on 12 of the 14 factors compared between the two stocks.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.